AIM ImmunoTech Inc.

OTCPK:AIMI Stock Report

Market Cap: US$7.6m

AIM ImmunoTech Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

OTCPK:AIMI Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
11 Apr 25BuyUS$5,000William MitchellIndividual196,851US$0.025
11 Apr 25BuyUS$50,000Thomas EquelsIndividual1,968,504US$0.025
11 Apr 25BuyUS$50,000Ted KellnerIndividual1,968,504US$0.025
04 Apr 25BuyUS$44Peter RodinoIndividual500US$0.087
04 Apr 25BuyUS$2,583Thomas EquelsIndividual41,000US$0.063
05 Mar 25BuyUS$6,730Thomas EquelsIndividual50,000US$0.13
04 Mar 25BuyUS$5,060Thomas EquelsIndividual44,000US$0.12
04 Mar 25BuyUS$10,000Thomas EquelsIndividual83,334US$0.12
19 Dec 24SellUS$884William MitchellIndividual4,580US$0.19
18 Dec 24BuyUS$4,682Thomas EquelsIndividual22,727US$0.21
02 Dec 24BuyUS$2,356Stewart AppelrouthIndividual11,112US$0.21
21 Nov 24BuyUS$4,240Thomas EquelsIndividual20,000US$0.21
20 Nov 24BuyUS$16,915Thomas EquelsIndividual85,000US$0.20
20 Nov 24BuyUS$11,000Thomas EquelsIndividual60,110US$0.18
20 Nov 24BuyUS$15,817Stewart AppelrouthIndividual81,953US$0.19
16 Sep 24BuyUS$1,515Thomas EquelsIndividual5,000US$0.30
13 Sep 24BuyUS$6,160Thomas EquelsIndividual20,000US$0.31

Insider Trading Volume

Insider Buying: AIMI insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of AIMI?
Owner TypeNumber of SharesOwnership Percentage
Institutions8,079,51511.2%
Individual Insiders11,877,73316.4%
General Public52,332,78272.4%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 42.1%.

Top Shareholders

Top 25 shareholders own 28.1% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
6.93%
Ted Kellner
5,007,504US$525.8k216%no data
5.35%
Thomas Equels
3,867,533US$406.1k130%no data
4.63%
Armistice Capital LLC
3,349,740US$351.7k-22.6%0.01%
3.38%
The Vanguard Group, Inc.
2,444,319US$256.7k22.9%no data
2.37%
Todd Deutsch
1,716,100US$180.2k0%no data
0.97%
BlackRock, Inc.
698,267US$73.3k0%no data
0.72%
William Mitchell
522,103US$54.8k259%no data
0.64%
Geode Capital Management, LLC
464,016US$48.7k0%no data
0.56%
Peter Rodino
401,762US$42.2k0.12%no data
0.5%
Citadel Advisors LLC
358,987US$37.7k-21.6%no data
0.4%
Nancy Bryan
291,882US$30.6k161%no data
0.36%
Renaissance Technologies LLC
260,479US$27.3k7.1%no data
0.24%
State Street Global Advisors, Inc.
173,103US$18.2k0%no data
0.24%
Verition Fund Management LLC
171,000US$18.0k11.8%no data
0.12%
Northern Trust Global Investments
85,119US$8.9k0%no data
0.12%
XTX Holdings Limited, Asset Management Arm
83,509US$8.8k69.7%no data
0.11%
Morgan Stanley, Investment Banking and Brokerage Investments
76,320US$8.0k-9.49%no data
0.099%
Two Sigma Securities, LLC, Asset Management Arm
71,305US$7.5k0%no data
0.089%
David Chemerow
64,189US$6.7k0%no data
0.063%
Crescent Grove Advisors, LLC
45,390US$4.8k0%no data
0.053%
Susquehanna International Group, LLP, Asset Management Arm
38,040US$4.0k0%no data
0.051%
Virtu Financial LLC, Asset Management Arm
36,658US$3.8k-64.1%no data
0.049%
SeaCrest Wealth Management, LLC
35,063US$3.7k0%no data
0.044%
Hudson River Trading LLC, Asset Management Arm
31,648US$3.3k-8.91%no data
0.028%
CapFinancial Partners, LLC, Asset Management Arm
20,000US$2.1k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/12 20:29
End of Day Share Price 2025/05/09 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

AIM ImmunoTech Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Edward WooAscendiant Capital Markets LLC
Ling WangChardan Capital Markets, LLC
Pravin GondhaleVirtua Research Inc.